In This Article:
-
Cash Used in Operations: $119.2 million for the full year 2024, within the guidance range of $114 million to $120 million.
-
Net Loss: $155.1 million or $2.30 per share for the year ended December 31, 2024, compared to $118.5 million or $2.32 per share in 2023.
-
Non-Cash Share-Based Compensation: $19.5 million in 2024, up from $17.3 million in 2023.
-
R&D Expenses: $119 million in 2024, compared to $87.5 million in 2023.
-
G&A Expenses: $59.2 million in 2024, compared to $49.4 million in 2023.
-
Debt: $30.2 million under the Hercules loan facility at the end of Q4 2024.
-
Cash and Cash Equivalents: $165.1 million as of December 31, 2024.
-
Recent Financing: Net proceeds of approximately $140 million in January 2025.
-
2025 Financial Guidance: Expected net cash used in operations to be within the range of $120 million to $145 million.
Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Compass Pathways PLC (NASDAQ:CMPS) has secured financing that positions the company to complete the COMP360 program in treatment-resistant depression (TRD) and progress the PTSD development program.
-
The company has recruited over 90% of patients for the 005 trial, indicating strong progress towards completing enrollment.
-
Compass Pathways PLC (NASDAQ:CMPS) is on track to report top-line results from the 005 trial in the second quarter of 2025, providing key efficacy measures.
-
The recent financing provides a financial runway to fund operations through the planned 26-week data readout from the COMP006 study, expected in the second half of 2026.
-
Strategic collaborations with healthcare delivery organizations are providing valuable insights into care settings, aiding in the strategy for launch and post-launch scaling.
Negative Points
-
The company reported a net loss of $155.1 million for the year ended December 31, 2024, compared to a net loss of $118.5 million in 2023.
-
Research and development expenses increased significantly to $119 million in 2024 from $87.5 million in the prior year.
-
General and administrative expenses also rose to $59.2 million in 2024 from $49.4 million in the previous year.
-
The company has debt under the Hercules loan facility amounting to $30.2 million at the end of the fourth quarter.
-
There is uncertainty regarding the regulatory path and the specific requirements for the PTSD program, as discussions with the FDA are ongoing.
Q & A Highlights
Q: What is the expected benchmark for the six-week Madras delta in the COMP005 trial? A: Kabir Nath, CEO, stated that the phase 2B six-week data is being used as a benchmark for the phase three studies. The clinically meaningful effect size is lower, but the phase 2B data serves as a guide for planning the phase three trials.